Revance Therapeutics, Inc. (RVNC)
| Market Cap | 1.82B |
| Revenue (ttm) | 15.33M |
| Net Income (ttm) | -282.09M |
| Shares Out | 58.01M |
| EPS (ttm) | -4.86 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | March 3 |
| Last Price | $25.80 |
| Previous Close | $26.06 |
| Change ($) | -0.26 |
| Change (%) | -1.00% |
| Day's Open | 26.13 |
| Day's Range | 25.52 - 26.65 |
| Day's Volume | 776,587 |
| 52-Week Range | 11.78 - 34.62 |
NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance to Participate in Upcoming Virtual Healthcare Conferences
Dublin, Feb. 24, 2021 (GLOBE NEWSWIRE) -- The "Facial Injectable Market - Forecasts from 2020 to 2025" report has been added to ResearchAndMarkets.com's offering. The facial injectable market ...
NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO--(BUSINESS WIRE)--Ambrx Appoints Audit Executive Chris Nolet to Board of Directors
Revance Therapeutics Inc (NASDAQ: RVNC) has reported topline data from JUNIPER Phase 2 study evaluating DaxibotulinumtoxinA for Injection to treat adults with moderate to severe upper limb spa...
Shares of Revance Therapeutics (NASDAQ:RVNC) increased in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share fell 25.25% year over year to ($1.24)...
NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Announces Positive Topline Phase 2 Data Supporting Advancement of DaxibotulinumtoxinA for Injection for the Treatment of ULS
NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Reports Fourth Quarter and Full Year 2020 Financial Results
NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Appoints Olivia C. Ware and Carey O'Connor Kolaja to Board of Directors
On Monday, February 22, Revance Therapeutics (NASDAQ:RVNC) will release its latest earnings report. Benzinga's outlook for Revance Therapeutics is included in the following report.
NASHVILLE, Tenn.--(BUSINESS WIRE)--Governor Lee, Commissioner Rolfe Announce Revance Therapeutics to Relocate Global Headquarters to Nashville
Revance (RVNC) announces a delay in the FDA decision on its BLA for DaxibotulinumtoxinA for Injection due to COVID-19.
Revance Therapeutics, Inc. (RVNC) CEO Mark Foley on Q3 2020 Results - Earnings Call Transcript
Shares of Revance Therapeutics (NASDAQ:RVNC) decreased 8.62% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share were down 39.58% year over year...
Revance (RVNC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Revance Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating. The post Stocks Showing Market Leadership: Revance Therapeutics Earns 93 RS Rati...
Revance Therapeutics, Inc. (RVNC) CEO Mark Foley on Q2 2020 Results - Earnings Call Transcript
Revance Therapeutics (RVNC) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Revance Therapeutics, Inc. (RVNC) CEO Mark Foley on Q1 2020 Results - Earnings Call Transcript
As of late, it has definitely been a great time to be an investor in Revance Therapeutics.
Revance (RVNC) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Investors need to pay close attention to Revance Therapeutics (RVNC) stock based on the movements in the options market lately.
Revance Therapeutics, Inc. (RVNC) CEO Mark Foley on Q4 2019 Results - Earnings Call Transcript
The company's frown line treatment moved closer to commercialization today.
As of late, it has definitely been a great time to be an investor in Revance Therapeutics.
A new deal accelerates the company's shift to a commercial-stage biotech.
Revance Therapeutics: The Real Threat To Abbvie's Dividend
Several companies raised capital on Wednesday.
The pricing of a secondary offering is to blame.
Revance Therapeutics, Inc. (RVNC) CEO Mark Foley on Q3 2019 Results - Earnings Call Transcript
Earlier this month, Revance Therapeutics Inc (NASDAQ: RVNC) named Mark Foley as its new CEO.
Possible merger and acquisition activity lifted one of these stocks.
Biotech Revance Therapeutics Inc. RVNC, +4.46% said Monday it has named Mark J. Foley as chief executive, replacing Dan Browne who has stepped down due to a misjudgment in handling an employee...
Revance's DAXI seems to have a longer duration of effect than botox and its current competitors.
These 10 monster growth stocks to buy all offer exciting opportunities. There's the important information for investors to keep in mind.
Revance Therapeutics, Inc. (RVNC) CEO Daniel Browne on Q2 2019 Results - Earnings Call Transcript
Revance (RVNC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Revance's share price has been battered over the past year.
Revance Therapeutics (RVNC) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Revance Therapeutics, Inc. (RVNC) on Q1 2019 Results - Earnings Call Transcript
Revance (RVNC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Revance Therapeutics CEO: Challenging Allergan
A new wrinkle to an old treatment helped the stock of Revance Therapeutics nearly double in 2017. Could its competitive streak against Allergan help push the company even higher? Jim Cramer as...
About RVNC
Revance Therapeutics, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection (DAXI) which competed phase 3 clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; in phase 2 clinical trials to treat adult upper limb spasticity and plantar fasciitis, and in pre-clinical trials to treat chronic migraine. It ... [Read more...]
| Industry Biotechnology | IPO Date Feb 6, 2014 |
| CEO Mark Foley | Employees 470 |
| Stock Exchange NASDAQ | Ticker Symbol RVNC |
Financial Performance
In 2020, RVNC's revenue was $15.33 million, an increase of 3,610.65% compared to the previous year's $413,000. Losses were -$282.09 million, 76.9% more than in 2019.
Analyst Forecasts
According to 11 analysts, the average rating for RVNC stock is "Buy." The 12-month stock price forecast is 37.80, which is an increase of 46.51% from the latest price.